Paradigm Medical Industries, Inc.
Zur Info, am 24.04.07 gabs wieder News von Paradigm!
Hier geht es wohl um eine neue Software für die Ultraschall-Geräte.
Mal sehen, am 20. Mai kommen angeblich Zahlen - ich hoffe der Kurs explodiert dann wieder! :-) Habe mir zumindest die letzten Wochen noch ein paar billige Stücke gesichert!
Paradigm Medical Industries Developing New Software for P60 UBM Device
Apr 24, 2007 9:17:00 AM
Copyright Business Wire 2007
SALT LAKE CITY--(BUSINESS WIRE)--
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB), a leading innovative producer of ultrasound devices for the ophthalmic and medical industries, disclosed today it is developing the next generation of Ultrasound software for its P60 Ultrasound BioMicroscope (UBM) through a partnership with Reliacon Global, Inc. (RGI). A prototype of the new software will be available at the upcoming American Society of Cataract and Refractive Surgeons' (ASCRS) Conference in San Diego, beginning April 28, 2007.
"Although we already have exceptional Ultrasound imaging technology, the Company felt there is opportunity for significant improvement through a developmental program with RGI," said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "We also believe there is a need to improve our database management system. With the patient record management changes taking place throughout the medical industry, the Company decided to get ahead of the curve and help establish the benchmark for imaging related ophthalmic patient database management."
The P60 UBM is Paradigm Medical's fourth-generation device that is a sophisticated microprocessor-based, multi-frequency Ultrasound BioMicroscope that allows practitioners to acquire and view high-resolution images of the anterior segment of the eye. The P60 is used for imaging of vital structures of the eye, primarily the front half of the eye. Imaging of the anterior chamber angle is one of the principal areas studied in the detection of glaucoma pathologies and related surgical filtering. The P60 UBM has been approved by regulatory agencies in the United States, Canada, Western Europe, Middle East, South America, and most of the Pacific Rim.
Reliacon Global, Inc., is a venture founded by Dr. Bert Massie, former chief executive of Massie Laboratories, Inc. Dr. Massie and his team originally developed the image capture and database management system utilized in the Massie Laboratories RetCam pediatric ophthalmic imaging device.
The new software will be installed in all new P60 UBM's delivered by the Company after July 2007. The new software will also be made available to the current owners of the P60 devices placed into service globally since the P60 was introduced in 2005.
Upon completion of the new P60 software project, RGI will begin redesigning the functionality of the Company's LD400 AutoPerimeter. "Paradigm Medical has been the leader in the field of Kinetic Fixation visual field analysis and will continue to remain in the lead with the anticipated new look and functionality of the LD400," Mr. Cannefax noted. The LD400 AutoPerimeter is used to measure patient visual fields.
Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed "The UBM Company" (Ultrasound BioMicroscope). Contact us at 801-977-8970 or visit us at www.paradigm-medical.com.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Source: Paradigm Medical Industries, Inc.
----------------------------------------------
Paradigm Medical Industries
Inc.
Raymond Cannefax
CEO
801-977-8970
Hoffe nun auch mal auf die Zahlen und einen hoffentlich damit verbundenen Kursanstieg.
@ralf45: Hoffe Du hast wenigstens andere Stocks, mit denen Du den jetzigen Verlust ausgleichen kannst. Aber bald dreht sich ja hier der Kurs :-)
So long. Immer schön bullish denken ( auch wenn´s schwer fällt )!!!
mit meinem Depot bin ich noch immer im grünen Bereich. Mich rührt die
Fürsorge, nur Paradigm + A0F5X0 bin ich weit im Minus.
schönes Wochenende und hoffen wir auf Anfang Mai
Gruß
Paddybroker
und wieder runter.
Je nachdem wie die Q- Zahlen ausfallen, sollte ein "kleines Feuerwerk" :-) doch auch möglich sein.
In diesem Sinne. Immer bullish denken.
Paddybroker
Dann könnte sogar ein "großes Feuerwerk" möglich sein.
Stern
Paddybroker
Letztes Jahr waren sie am 22. Mai da. Hoffe mal, das die Zahlen für sich sprechen und das Unternehmen wieder Fahrt aufnimmt. Der aktuelle Kurs ist ja eher ein Witz. Auch die Bid Seite heute in Frankfurt mit 0,001 spricht für sich. Ich bleibe weiter investiert und gebe die Hoffnung auf einen baldigen Anstieg nicht auf.
So long
Noch jemand hier im Forum ? Mit den Q-Zahlen lassen sich die Herren und Damen aber Zeit. Habe mal eine Mail an den Laden geschickt, wann denn die Zahlen kommen. Hoffe ich bekomme eine Antwort von dort. Der Kurs dümpelt ja vor sich hin. Hoffe nicht mehr lange. Sollten die Zahlen positiv ausfallen, sollte sich das auf den Kurs auswirken.
Falls jemand was näheres zu Zahlen oder News weiss, wäre es schön, wenn es ins Forum gestellt wird. Ansonsten heißt es durchhalten. Sollte sich doch auszahlen; oder?
So long
Paddybroker
langsam komm ich mir ein wenig verar...t vor. Wann kommen denn endlich mal Q- Zahlen oder mal Nachrichten über sie Situation bei Paradigm ? Angeblich sollten vor 1 Monat schon Zahlen kommen. Habe denen mal eine e-mail geschickt und nachgefragt, aber keine Antwort bekommen. Weiß jemand hier im Thread mehr ? Hoffe für uns alle, daß sich bald mal was tut.Ist noch jemand hier ???
Gruß
Paddybroker
Paddybroker
Auf eine hoffentlich positive Zukunft mit Paradigm.
So long
Paddybroker
Gibt's News? Weiß jemand was?
Friday October 26, 8:51 am ET
SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries’ (OTCBB: PMED.OB/PMEDW.OB) Chief Executive Officer, Raymond Cannefax, today outlined the Company’s plan to achieve profitability and positive cash flow in a special report to shareholders. Following is the complete text of Mr. Cannefax’s Letter to Shareholders
October 26, 2007
Dear Shareholder:
While 2007 results won’t be finalized for several more months, and our preliminary budgeting process has only just begun, the Company believes now is an appropriate time to communicate its progress and plans for the future.
Paradigm Medical Industries has been through turbulent times during the last few years. And much has happened in the last 20 months, since I was named Chief Executive Officer. Further, 2007 has been a year of major transition for the Company.
My message to you today is we have met many challenges and obstacles and are now poised to make substantial progress in the Company’s major goals of reaching profitability and consistent positive cash flow and enhancing shareholder value.
Hidden within the Company’s most recent quarterly financial results are several “pluses” that provide optimism for Paradigm Medical’s strategies, goals, and commitment. Specifically:
(1) We have substantially reduced the Company’s operating expenses without sacrificing quality and have improved on-time delivery. During the last five years, we have reduced the Company’s annual operating expenses by $9.5 million.
(2) We have refocused and reformulated the Company’s product portfolio into high-margin, fast-growing proprietary products. Paradigm Medical is clearly the most unique, full-service provider of Ultrasound devices to the ophthalmic industry.
(3) We have become more globally oriented with our U.S. and international regulatory-approved products. And we have already established foot prints in the fastest-growing regions of the world, namely Asia and East Europe. A major part of this success has been the establishment of partnerships with leading developers and producers of ultrasound devices like China’s MEDA Co. Ltd., and new-generation software with innovative companies like Reliacon Global (San Ramon, CA).
(4) We have resolved long-standing litigation matters without jeopardizing the Company’s financial and operational structure.
(5) We have strengthened the Company’s financial structure with the completion of several fundings, completed in 2005 and 2006, that have allowed us to upgrade our facilities and further advance our research and development programs.
(6) Organizationally, we now have a professional management team in place that is dedicated and capable of achieving the corporate strategy with a viable business model that compliments the Company’s strengths. And we have, this year, significantly upgraded our global sales and marketing efforts to allow us to move aggressively into the “growth” phase of our matrix.
Our financial results for 2007 will be relatively flat, compared with the year-ago period. Our revenues will be stable, and our operating loss will widen slightly. Clearly, that is unacceptable. Nonetheless, during a year when “uncontrollable” costs--such as higher raw material and energy bills--soared, and we incurred significant expense (some one-time) on a global launching of our new-generation P60 Ultrasound BioMicroscope (UBM), as well as considerable management time in resolving financial and legal issues, the Company made substantial progress toward reaching some short-term and intermediate-term goals.
Since 2002, the Company has reduced its operating expense by $9.5 million. In 2007, such expense will be somewhat higher than a year ago. However, a good part of the increase reflects higher costs associated with launching the P60 (including costs in receiving U.S. and international regulatory approvals) and dramatically expanding and repositioning marketing and distribution channels.
Since 2002, the Company improved its gross profit margin from 21.6% to more than 50%. Again, our margin will be somewhat lower in 2007 than a year ago. The major factor in the decline reflects lower revenues—as we reposition our portfolio toward higher-margin, proprietary products—and higher fixed and variable costs (especially energy).
The results—and rewards—for our actions are expected to be more visible in 2008 and beyond.
Specifically, the Company will be entering a fast-track path in revenue and margin growth. By the end of 2008, our goal is to be at an annualized revenue run-rate of $4 million. We believe gross profit margin will be at least 50% (likely higher), which would result in gross profit of $2 million.
Our indirect expense (e.g., selling, general, administrative, and research and development costs) will likely approximate $2 million. The “bottom line” for us is break even. This will mark a dramatic change in our financial performance, where losses have exceeded $1.0-3.4 million annually during the last few years. Management’s ability to control costs and improve operating margins could enhance the 2008 results.
More importantly, our goal is to be slightly cash flow positive by the end of 2008. Again, this will reflect a dramatic improvement from our recent year “negative” cash flows. We view our cash flow performance as one of the true benchmarks of determining the success of our corporate goals.
During the next 24 months the Company’s goal is to reach annualized sales of $5 million, and gross profit of $2.75 million. Management is committed to maintaining an indirect expense level of $2.5 million during that timeframe. At such performance levels, Paradigm Medical would generate a modest profit from operations and achieve consistently positive cash flow.
Is the goal “reasonable?” We believe so. More importantly, is it “achievable?”
Barring unforeseen external events, management believes the successful launch and global growth of our new-generation Ultrasound devices, coupled with a rededication to our Blood Flow Analyzer™ and the introduction of at least six new product offerings could bolster the base sales level and help expand the Company’s gross profit margin by several basis points.
Paradigm Medical has already achieved substantial reduction in its operating expenses and has isolated areas for additional savings. These can be achieved without penalizing the integrity of our operations. And the higher costs associated with expanding our global sales team and efforts will be offset by the higher revenues and margins we are projecting.
Too often, programs aimed at substantially reducing expenses underscore a company’s maturing and subsequent decline. This is not the case at Paradigm Medical. Reducing expense was a starting point in our strategy of growth, not a stopgap approach to combat complacency. Our manufacturing efficiency has made a quantum leap during the last 18-24 months. Our on-spec and on-time delivery performance has been outstanding.
We have successfully launched a new generation of proprietary devices and carefully scrutinized our product mix. We are more product focused and performance oriented. We believe we are able to meet the challenges ahead and reward our patient shareholders and customers and our outstanding and loyal employees.
Sincerely,
Raymond Cannefax
President and Chief Executive Officer
Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed “The UBM Company” (Ultrasound BioMicroscope). Contact us at 801-977-8970 or visit us at www.paradigm-medical.com.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Contact:
Paradigm Medical Industries, Inc.
Raymond Cannefax, CEO
801-977-8970